Report Categories Report Categories

Report Categories

industry Category

All

Total: 2 records, 1 pages

Global Anti-VEGF Therapies Supply, Demand and Key Producers, 2024-2030

date 25 Jul 2024

date Medical Care

new_biaoQian Anti-VEGF Therapies

Angiogenesis, the generation of new blood vessels, is an essential physiological process that can be dysregulated in various pathological conditions, including cancer. The vascular endothelial growth factor (VEGF) pathway is considered the most important and is a well-characterized contributor to angiogenesis. VEGF-A and other members of the VEGF family such as placental growth factor (PlGF) are upregulated in pathological conditions. VEGF-A, the first VEGF characterized, has served as a paradigm for the development of antiangiogenesis as a therapeutic strategy.

USD4480.00

Add To Cart

Add To Cart

Global Anti-VEGF Therapies Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 25 Jul 2024

date Medical Care

new_biaoQian Anti-VEGF Therapies

Angiogenesis, the generation of new blood vessels, is an essential physiological process that can be dysregulated in various pathological conditions, including cancer. The vascular endothelial growth factor (VEGF) pathway is considered the most important and is a well-characterized contributor to angiogenesis. VEGF-A and other members of the VEGF family such as placental growth factor (PlGF) are upregulated in pathological conditions. VEGF-A, the first VEGF characterized, has served as a paradigm for the development of antiangiogenesis as a therapeutic strategy.

USD3480.00

Add To Cart

Add To Cart

industry 25 Jul 2024

industry Medical Care

new_biaoQian Anti-VEGF Therapies

Angiogenesis, the generation of new blood vessels, is an essential physiological process that can be dysregulated in various pathological conditions, including cancer. The vascular endothelial growth factor (VEGF) pathway is considered the most important and is a well-characterized contributor to angiogenesis. VEGF-A and other members of the VEGF family such as placental growth factor (PlGF) are upregulated in pathological conditions. VEGF-A, the first VEGF characterized, has served as a paradigm for the development of antiangiogenesis as a therapeutic strategy.

USD4480.00

addToCart

Add To Cart

industry 25 Jul 2024

industry Medical Care

new_biaoQian Anti-VEGF Therapies

Angiogenesis, the generation of new blood vessels, is an essential physiological process that can be dysregulated in various pathological conditions, including cancer. The vascular endothelial growth factor (VEGF) pathway is considered the most important and is a well-characterized contributor to angiogenesis. VEGF-A and other members of the VEGF family such as placental growth factor (PlGF) are upregulated in pathological conditions. VEGF-A, the first VEGF characterized, has served as a paradigm for the development of antiangiogenesis as a therapeutic strategy.

USD3480.00

addToCart

Add To Cart